The FDA has granted Breakthrough Therapy designation to Lilly’s investigational KRAS G12C inhibitor olomorasib for previously treated advanced pancreatic cancer, based on encouraging Phase 1/2 LOXO-RAS-20001 clinical trial results.
Written By: Meghana Jinka, PharmD
Reviewed By: Pharmacally Editorial Team
Eli Lilly and Company has received U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation for olomorasib as monotherapy for adults with advanced pancreatic cancer harboring a KRAS G12C mutation who have received at least one prior systemic therapy. The designation recognizes promising preliminary clinical evidence suggesting the investigational therapy may offer a substantial improvement over currently available treatments in a disease with few effective options.
The latest designation adds to olomorasib’s growing regulatory momentum. The FDA had previously granted Breakthrough Therapy designation for olomorasib in combination with pembrolizumab (Keytruda) as first-line treatment for patients with KRAS G12C-mutant, PD-L1-positive advanced non-small cell lung cancer (NSCLC).
Olomorasib Targets a Challenging Oncogenic Driver
Olomorasib (LY3537982) is an investigational, oral, next-generation KRAS G12C inhibitor developed to selectively and potently inhibit the mutant KRAS G12C protein. Its pharmacokinetic profile supports sustained target occupancy, allowing high potency both as monotherapy and in combination regimens.
KRAS mutations account for approximately 90% of pancreatic cancers, although the KRAS G12C subtype represents only about 1% to 2% of cases. Despite its relatively low prevalence, patients with KRAS G12C-mutant pancreatic cancer generally experience poor outcomes and currently lack any approved mutation-specific targeted therapy.
Pancreatic cancer remains one of the deadliest malignancies worldwide. Around 60,000 people are diagnosed annually in the United States, with approximately 50,000 deaths each year. The five-year survival rate for metastatic disease remains below 5%, underscoring the urgent need for more effective therapies.
Breakthrough Designation Supported by Phase 1/2 LOXO-RAS-20001 Study
The FDA based its decision on encouraging preliminary data from the Phase 1/2 LOXO-RAS-20001 trial (NCT04956640), an ongoing open-label, multicenter study evaluating olomorasib in patients with KRAS G12C-mutant advanced solid tumors, including pancreatic cancer.
The trial includes a Phase 1 dose-escalation component evaluating olomorasib monotherapy, followed by dose-expansion and optimization cohorts investigating the drug alone and in combination with other anticancer therapies. The study primarily evaluates safety, tolerability, pharmacokinetics, and preliminary antitumor activity across multiple KRAS G12C-driven malignancies.
Although Lilly has not released detailed efficacy data from the pancreatic cancer cohort, the FDA determined that the early clinical evidence met the threshold required for Breakthrough Therapy designation, which is reserved for investigational therapies that may provide meaningful improvements over available treatments for serious diseases.
Regulatory Milestone Reflects Broader KRAS G12C Development Strategy
Jacob Van Naarden, executive vice president and president of Lilly Oncology, said patients with KRAS G12C-mutant pancreatic cancer have limited treatment options once their disease progresses. He noted that the FDA designation reflects both the encouraging early clinical activity observed with olomorasib and the significant unmet medical need in this setting.
He added that olomorasib has now received two FDA Breakthrough Therapy designations across pancreatic and lung cancers, reinforcing its potential across multiple KRAS G12C-driven tumors.
Multiple Registrational Studies Continue
Lilly continues to expand the clinical development program for olomorasib beyond pancreatic cancer.
The investigational agent is being evaluated in the ongoing LOXO-RAS-20001 Phase 1/2 study across advanced solid tumors and in the pivotal SUNRAY-01 (NCT06119581) registrational trial, which is assessing olomorasib combined with pembrolizumab, with or without chemotherapy, as first-line treatment for advanced KRAS G12C-mutant NSCLC. The company is also conducting the global SUNRAY-02 (NCT06890598) study evaluating olomorasib with standard immunotherapy in patients with resected or unresectable KRAS G12C-mutant NSCLC.
The latest FDA designation is expected to facilitate closer regulatory interaction and potentially accelerate the development and review of olomorasib as Lilly advances its targeted oncology portfolio across KRAS G12C-driven cancers.
Reference
About the Writer
Meghana Jinka (LinkedIn) is a Pharm.D graduate with a strong interest in clinical pharmacy, clinical research, pharmacovigilance, and medical writing. She has developed expertise in evaluating scientific literature, interpreting clinical data, and communicating complex medical information in a clear and accessible manner. Through clinical training, patient counseling, and healthcare awareness activities, she has gained practical experience in evidence-based medicine and patient-centered care. Passionate about healthcare communication, Meghana is committed to developing accurate, engaging, and evidence-based healthcare documents that support healthcare professionals and the wider community.